Review



lg lane recombinant human caiii  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    R&D Systems lg lane recombinant human caiii
    Figure 2 (a) Western blot showing reactivity to <t>recombinant</t> carbonic anhydrase III <t>(CAIII)</t> in serum from patients with vasculitis. Lane 1, serum from patient with polyarteritis nodosa (PAN), lane 2, serum from patient with Takayasu’s arteritis (TA), lane 3, serum from patient with Wegener’s granulomatosis (WG), lane 4, serum from patient with micro- scopic polyangiitis (MPA). Blot reactivity was observed in serum samples from patients with TA and MPA (lanes 2, 4). (b) Western blotting with non-treated serum and absorbed serum. Lane 1, Western blotting with serum incubated with recombinant CAIII to absorb anti-CAIII antibodies before blotting. Lane 2, Western blotting with serum from patient with untreated MPA.
    Lg Lane Recombinant Human Caiii, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lg+lane+recombinant+human+caiii/Recombinant+Human+Carbonic+Anhydrase+III+Protein%2C+CF/10__1111_slash_1756___185x__12089-59-15-19
    Average 90 stars, based on 2 article reviews
    lg lane recombinant human caiii - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "Anti-carbonic anhydrase III autoantibodies in vasculitis syndrome"

    Article Title: Anti-carbonic anhydrase III autoantibodies in vasculitis syndrome

    Journal: International Journal of Rheumatic Diseases

    doi: 10.1111/1756-185x.12089

    Figure 2 (a) Western blot showing reactivity to recombinant carbonic anhydrase III (CAIII) in serum from patients with vasculitis. Lane 1, serum from patient with polyarteritis nodosa (PAN), lane 2, serum from patient with Takayasu’s arteritis (TA), lane 3, serum from patient with Wegener’s granulomatosis (WG), lane 4, serum from patient with micro- scopic polyangiitis (MPA). Blot reactivity was observed in serum samples from patients with TA and MPA (lanes 2, 4). (b) Western blotting with non-treated serum and absorbed serum. Lane 1, Western blotting with serum incubated with recombinant CAIII to absorb anti-CAIII antibodies before blotting. Lane 2, Western blotting with serum from patient with untreated MPA.
    Figure Legend Snippet: Figure 2 (a) Western blot showing reactivity to recombinant carbonic anhydrase III (CAIII) in serum from patients with vasculitis. Lane 1, serum from patient with polyarteritis nodosa (PAN), lane 2, serum from patient with Takayasu’s arteritis (TA), lane 3, serum from patient with Wegener’s granulomatosis (WG), lane 4, serum from patient with micro- scopic polyangiitis (MPA). Blot reactivity was observed in serum samples from patients with TA and MPA (lanes 2, 4). (b) Western blotting with non-treated serum and absorbed serum. Lane 1, Western blotting with serum incubated with recombinant CAIII to absorb anti-CAIII antibodies before blotting. Lane 2, Western blotting with serum from patient with untreated MPA.

    Techniques Used: Western Blot, Recombinant, Incubation

    Figure 3 Quantitative analysis of immunoglobulin G (IgG) reactivity against the recombinant protein carbonic anhydrase III (CAIII) in individual serum sample of patients with vasculi- tis. Serum samples from 23 patients with microscopic polyan- giitis (MPA), 15 with Wegener’s granulomatosis (WG), 10 with polyarteritis nodosa (PAN), nine with Takayasu’s arteritis (TA), four with allergic granulomatous angiitis (AGA), and 32 healthy controls were incubated with recombinant CAIII immobilized onto an enzyme-linked immunosorbent assay plate. The mean optical density (OD) values for the recombi- nant protein were normalized by mean OD values of the back- ground immunoreactivity and expressed as arbitrary units (AU) based on the positive and negative reference sera. Hori- zontal lines indicate the mean for each group and the broken line indicates the cutoff level at the mean + 2 standard devia- tions (SD) of the healthy control. In patients with MPA, 11 of 23 serum samples were positive for CAIII. In contrast, of the 32 healthy controls, two were positive for CAIII reactivity. The difference between patients with MPA and healthy controls was statistically significant (P < 0.001).
    Figure Legend Snippet: Figure 3 Quantitative analysis of immunoglobulin G (IgG) reactivity against the recombinant protein carbonic anhydrase III (CAIII) in individual serum sample of patients with vasculi- tis. Serum samples from 23 patients with microscopic polyan- giitis (MPA), 15 with Wegener’s granulomatosis (WG), 10 with polyarteritis nodosa (PAN), nine with Takayasu’s arteritis (TA), four with allergic granulomatous angiitis (AGA), and 32 healthy controls were incubated with recombinant CAIII immobilized onto an enzyme-linked immunosorbent assay plate. The mean optical density (OD) values for the recombi- nant protein were normalized by mean OD values of the back- ground immunoreactivity and expressed as arbitrary units (AU) based on the positive and negative reference sera. Hori- zontal lines indicate the mean for each group and the broken line indicates the cutoff level at the mean + 2 standard devia- tions (SD) of the healthy control. In patients with MPA, 11 of 23 serum samples were positive for CAIII. In contrast, of the 32 healthy controls, two were positive for CAIII reactivity. The difference between patients with MPA and healthy controls was statistically significant (P < 0.001).

    Techniques Used: Recombinant, Incubation, Enzyme-linked Immunosorbent Assay, Control

    Figure 4 Comparison between carbonic anhydrase III (CAIII) enzyme-linked immunosorbent assay values and vasculitis disease activity (Birmingham vasculitis activity scores, BVAS). Patients with microscopic polyangiitis (MPA) were divided into two groups, the anti-CAIII-positive group and anti- CAIII-negative group. BVAS were significantly higher in the anti-CAIII-positive group compared to the anti-CAIII-negative group. Horizontal bars indicate the median BVAS in each group.
    Figure Legend Snippet: Figure 4 Comparison between carbonic anhydrase III (CAIII) enzyme-linked immunosorbent assay values and vasculitis disease activity (Birmingham vasculitis activity scores, BVAS). Patients with microscopic polyangiitis (MPA) were divided into two groups, the anti-CAIII-positive group and anti- CAIII-negative group. BVAS were significantly higher in the anti-CAIII-positive group compared to the anti-CAIII-negative group. Horizontal bars indicate the median BVAS in each group.

    Techniques Used: Comparison, Enzyme-linked Immunosorbent Assay, Activity Assay

    Related Articles

    Western Blot:

    Article Title: Anti-carbonic anhydrase III autoantibodies in vasculitis syndrome
    Article Snippet: .. Western blotting using recombinant CAIII as antigen For detection of IgG antibodies to CAIII, 1 lg/lane recombinant human CAIII (R&D Systems, Inc., Minneapolis, MN, USA) was subjected to 15% SDS-PAGE under reducing conditions, and transferred onto PVDF membrane. ..

    Recombinant:

    Article Title: Anti-carbonic anhydrase III autoantibodies in vasculitis syndrome
    Article Snippet: .. Western blotting using recombinant CAIII as antigen For detection of IgG antibodies to CAIII, 1 lg/lane recombinant human CAIII (R&D Systems, Inc., Minneapolis, MN, USA) was subjected to 15% SDS-PAGE under reducing conditions, and transferred onto PVDF membrane. ..

    SDS Page:

    Article Title: Anti-carbonic anhydrase III autoantibodies in vasculitis syndrome
    Article Snippet: .. Western blotting using recombinant CAIII as antigen For detection of IgG antibodies to CAIII, 1 lg/lane recombinant human CAIII (R&D Systems, Inc., Minneapolis, MN, USA) was subjected to 15% SDS-PAGE under reducing conditions, and transferred onto PVDF membrane. ..

    Membrane:

    Article Title: Anti-carbonic anhydrase III autoantibodies in vasculitis syndrome
    Article Snippet: .. Western blotting using recombinant CAIII as antigen For detection of IgG antibodies to CAIII, 1 lg/lane recombinant human CAIII (R&D Systems, Inc., Minneapolis, MN, USA) was subjected to 15% SDS-PAGE under reducing conditions, and transferred onto PVDF membrane. ..



    Similar Products

    lg lane recombinant human caiii  (R&D Systems)
    90
    R&D Systems lg lane recombinant human caiii
    Figure 2 (a) Western blot showing reactivity to <t>recombinant</t> carbonic anhydrase III <t>(CAIII)</t> in serum from patients with vasculitis. Lane 1, serum from patient with polyarteritis nodosa (PAN), lane 2, serum from patient with Takayasu’s arteritis (TA), lane 3, serum from patient with Wegener’s granulomatosis (WG), lane 4, serum from patient with micro- scopic polyangiitis (MPA). Blot reactivity was observed in serum samples from patients with TA and MPA (lanes 2, 4). (b) Western blotting with non-treated serum and absorbed serum. Lane 1, Western blotting with serum incubated with recombinant CAIII to absorb anti-CAIII antibodies before blotting. Lane 2, Western blotting with serum from patient with untreated MPA.
    Lg Lane Recombinant Human Caiii, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lg+lane+recombinant+human+caiii/Recombinant+Human+Carbonic+Anhydrase+III+Protein%2C+CF/10__1111_slash_1756___185x__12089-59-15-19
    Average 90 stars, based on 1 article reviews
    lg lane recombinant human caiii - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 2 (a) Western blot showing reactivity to recombinant carbonic anhydrase III (CAIII) in serum from patients with vasculitis. Lane 1, serum from patient with polyarteritis nodosa (PAN), lane 2, serum from patient with Takayasu’s arteritis (TA), lane 3, serum from patient with Wegener’s granulomatosis (WG), lane 4, serum from patient with micro- scopic polyangiitis (MPA). Blot reactivity was observed in serum samples from patients with TA and MPA (lanes 2, 4). (b) Western blotting with non-treated serum and absorbed serum. Lane 1, Western blotting with serum incubated with recombinant CAIII to absorb anti-CAIII antibodies before blotting. Lane 2, Western blotting with serum from patient with untreated MPA.

    Journal: International Journal of Rheumatic Diseases

    Article Title: Anti-carbonic anhydrase III autoantibodies in vasculitis syndrome

    doi: 10.1111/1756-185x.12089

    Figure Lengend Snippet: Figure 2 (a) Western blot showing reactivity to recombinant carbonic anhydrase III (CAIII) in serum from patients with vasculitis. Lane 1, serum from patient with polyarteritis nodosa (PAN), lane 2, serum from patient with Takayasu’s arteritis (TA), lane 3, serum from patient with Wegener’s granulomatosis (WG), lane 4, serum from patient with micro- scopic polyangiitis (MPA). Blot reactivity was observed in serum samples from patients with TA and MPA (lanes 2, 4). (b) Western blotting with non-treated serum and absorbed serum. Lane 1, Western blotting with serum incubated with recombinant CAIII to absorb anti-CAIII antibodies before blotting. Lane 2, Western blotting with serum from patient with untreated MPA.

    Article Snippet: Western blotting using recombinant CAIII as antigen For detection of IgG antibodies to CAIII, 1 lg/lane recombinant human CAIII (R&D Systems, Inc., Minneapolis, MN, USA) was subjected to 15% SDS-PAGE under reducing conditions, and transferred onto PVDF membrane.

    Techniques: Western Blot, Recombinant, Incubation

    Figure 3 Quantitative analysis of immunoglobulin G (IgG) reactivity against the recombinant protein carbonic anhydrase III (CAIII) in individual serum sample of patients with vasculi- tis. Serum samples from 23 patients with microscopic polyan- giitis (MPA), 15 with Wegener’s granulomatosis (WG), 10 with polyarteritis nodosa (PAN), nine with Takayasu’s arteritis (TA), four with allergic granulomatous angiitis (AGA), and 32 healthy controls were incubated with recombinant CAIII immobilized onto an enzyme-linked immunosorbent assay plate. The mean optical density (OD) values for the recombi- nant protein were normalized by mean OD values of the back- ground immunoreactivity and expressed as arbitrary units (AU) based on the positive and negative reference sera. Hori- zontal lines indicate the mean for each group and the broken line indicates the cutoff level at the mean + 2 standard devia- tions (SD) of the healthy control. In patients with MPA, 11 of 23 serum samples were positive for CAIII. In contrast, of the 32 healthy controls, two were positive for CAIII reactivity. The difference between patients with MPA and healthy controls was statistically significant (P < 0.001).

    Journal: International Journal of Rheumatic Diseases

    Article Title: Anti-carbonic anhydrase III autoantibodies in vasculitis syndrome

    doi: 10.1111/1756-185x.12089

    Figure Lengend Snippet: Figure 3 Quantitative analysis of immunoglobulin G (IgG) reactivity against the recombinant protein carbonic anhydrase III (CAIII) in individual serum sample of patients with vasculi- tis. Serum samples from 23 patients with microscopic polyan- giitis (MPA), 15 with Wegener’s granulomatosis (WG), 10 with polyarteritis nodosa (PAN), nine with Takayasu’s arteritis (TA), four with allergic granulomatous angiitis (AGA), and 32 healthy controls were incubated with recombinant CAIII immobilized onto an enzyme-linked immunosorbent assay plate. The mean optical density (OD) values for the recombi- nant protein were normalized by mean OD values of the back- ground immunoreactivity and expressed as arbitrary units (AU) based on the positive and negative reference sera. Hori- zontal lines indicate the mean for each group and the broken line indicates the cutoff level at the mean + 2 standard devia- tions (SD) of the healthy control. In patients with MPA, 11 of 23 serum samples were positive for CAIII. In contrast, of the 32 healthy controls, two were positive for CAIII reactivity. The difference between patients with MPA and healthy controls was statistically significant (P < 0.001).

    Article Snippet: Western blotting using recombinant CAIII as antigen For detection of IgG antibodies to CAIII, 1 lg/lane recombinant human CAIII (R&D Systems, Inc., Minneapolis, MN, USA) was subjected to 15% SDS-PAGE under reducing conditions, and transferred onto PVDF membrane.

    Techniques: Recombinant, Incubation, Enzyme-linked Immunosorbent Assay, Control

    Figure 4 Comparison between carbonic anhydrase III (CAIII) enzyme-linked immunosorbent assay values and vasculitis disease activity (Birmingham vasculitis activity scores, BVAS). Patients with microscopic polyangiitis (MPA) were divided into two groups, the anti-CAIII-positive group and anti- CAIII-negative group. BVAS were significantly higher in the anti-CAIII-positive group compared to the anti-CAIII-negative group. Horizontal bars indicate the median BVAS in each group.

    Journal: International Journal of Rheumatic Diseases

    Article Title: Anti-carbonic anhydrase III autoantibodies in vasculitis syndrome

    doi: 10.1111/1756-185x.12089

    Figure Lengend Snippet: Figure 4 Comparison between carbonic anhydrase III (CAIII) enzyme-linked immunosorbent assay values and vasculitis disease activity (Birmingham vasculitis activity scores, BVAS). Patients with microscopic polyangiitis (MPA) were divided into two groups, the anti-CAIII-positive group and anti- CAIII-negative group. BVAS were significantly higher in the anti-CAIII-positive group compared to the anti-CAIII-negative group. Horizontal bars indicate the median BVAS in each group.

    Article Snippet: Western blotting using recombinant CAIII as antigen For detection of IgG antibodies to CAIII, 1 lg/lane recombinant human CAIII (R&D Systems, Inc., Minneapolis, MN, USA) was subjected to 15% SDS-PAGE under reducing conditions, and transferred onto PVDF membrane.

    Techniques: Comparison, Enzyme-linked Immunosorbent Assay, Activity Assay